Skip Navigation
 

Collaborating with Nonprofits on Medical Research

Patient advocacy is evolving from direct influence to direct impact. As patients become not just advocates but active drivers in product development, pharmaceutical and biotech companies will need to adapt their research models to take advantage of patient input, data, and investment. FKH CEO Craig Martin framed the conversation as chair of a panel discussion, “Patient Advocacy and Your Next Generation of Research: How Nonprofit Organizations Can Accelerate Product Development,” at DIA 2012 on June 27. View his presentation here for a background on patient advocacy and research.